PROVEN TO CURE HEP C PATIENTS LIKE YOU
In a clinical study, VOSEVI had a 96% overall cure rate in adult patients who had Hep C genotype 1, 2, 3, 4, 5, or 6, without cirrhosis or with compensated cirrhosis,* who had been previously treated with certain advanced Hep C regimens.†
*Compensated cirrhosis is a type of advanced liver disease in which healthy liver tissue is replaced with scar tissue, but the liver is still able to carry out its important functions.
†In a study of 263 patients with genotype 1, 2, 3, 4, 5, or 6 Hep C, without cirrhosis or with compensated cirrhosis, who previously failed a Hep C regimen containing an NS5A inhibitor, 97% (146 out of 150) of patients with genotype 1, 100% (5 out of 5) of patients with genotype 2, 95% (74 out of 78) of patients with genotype 3, 91% (20 out of 22) of patients with genotype 4, 100% (1 out of 1) of patients with genotype 5, and 100% (6 out of 6) of patients with genotype 6 who received VOSEVI once daily for 12 weeks were cured. Cure means the Hep C virus is not detected in the blood when measured three months after treatment is completed.
SEE VOSEVI CLINICAL STUDY RESULTS
Important Safety Information
Who should not take VOSEVI?
- Do not take VOSEVI if you take medicines that contain rifampin (Rifater®, Rifamate®, Rimactane®, Rifadin®).
What should I tell my healthcare provider before taking VOSEVI?
- Tell your healthcare provider about all of your medical conditions, including if you have ever had hepatitis B infection or liver problems other than hepatitis C infection; if you have severe kidney problems or are on dialysis; or if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if VOSEVI will harm your unborn baby or pass into your breast milk.
- Tell your healthcare provider and pharmacist about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VOSEVI and certain other medicines may affect each other, or may cause side effects.